Literature DB >> 12566167

Distinguishing of primary cerebral lymphoma from high-grade glioma with perfusion-weighted magnetic resonance imaging.

Marius Hartmann1, Sabine Heiland, Inga Harting, Volker M Tronnier, Clemens Sommer, Roman Ludwig, Klaus Sartor.   

Abstract

To assess the usefulness of perfusion-weighted echo-planar magnetic resonance imaging in the differential diagnosis of primary supratentorial lymphoma (PCNSL) and glioblastoma (GBM), 12 patients with a PCNSL and 12 with a GBM were examined using a 1.5 T magnetic resonance (MR) imager. With dynamic-susceptibility contrast MR imaging the intensity-time curves of each tumor were analyzed, and we determined the relative regional cerebral blood volume ratios (rrCBV [tumor/contralateral white matter (WM)]) to find out whether these parameters could be used to separate PCNSL from GBM. The maximum rrCBV ratio in the PCNSL was significantly lower than that of the GBM (P<0.0001). Comparing the intensity-time curves for the two tumor groups, the PCNSL showed a characteristic type of curve with a significant increase in signal intensity above the baseline due to massive leakage of contrast media into the interstitial space. PCNSL tend to have low maximum CBV ratios and typical intensity-time curves. These two parameters may be useful in distinguishing PCNSL from GBM.

Entities:  

Mesh:

Year:  2003        PMID: 12566167     DOI: 10.1016/s0304-3940(02)01367-8

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  42 in total

1.  Percentage signal recovery derived from MR dynamic susceptibility contrast imaging is useful to differentiate common enhancing malignant lesions of the brain.

Authors:  R Mangla; B Kolar; T Zhu; J Zhong; J Almast; S Ekholm
Journal:  AJNR Am J Neuroradiol       Date:  2011-04-21       Impact factor: 3.825

2.  Dynamic susceptibility contrast-enhanced perfusion and conventional MR imaging findings for adult patients with cerebral primitive neuroectodermal tumors.

Authors:  Meng Law; Khuram Kazmi; Stephan Wetzel; Edwin Wang; Codrin Iacob; David Zagzag; John G Golfinos; Glyn Johnson
Journal:  AJNR Am J Neuroradiol       Date:  2004 Jun-Jul       Impact factor: 3.825

3.  Differentiation of primary central nervous system lymphomas from high-grade gliomas by rCBV and percentage of signal intensity recovery derived from dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging.

Authors:  Z Xing; R X You; J Li; Y Liu; D R Cao
Journal:  Clin Neuroradiol       Date:  2013-08-31       Impact factor: 3.649

4.  Cerebral gumma mimicking glioblastoma multiforme.

Authors:  Beau M Ances; Shabbar F Danish; Dennis L Kolson; Kevin D Judy; David S Liebeskind
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

Review 5.  [Corpus callosum. Landmark of the origin of cerebral diseases].

Authors:  E Hattingen; M Nichtweiss; S Blasel; F E Zanella; S Weidauer
Journal:  Radiologe       Date:  2010-02       Impact factor: 0.635

6.  Use of dynamic susceptibility-contrast MRI (DSC-MRI) to assess perfusion changes in the ipsilateral brain parenchyma from glioblastoma.

Authors:  Stephan Ulmer; Carsten Liess; Santosh Kesari; Nadine Otto; Torsten Straube; Olav Jansen
Journal:  J Neurooncol       Date:  2008-09-21       Impact factor: 4.130

7.  Permeability measurement using dynamic susceptibility contrast magnetic resonance imaging enhances differential diagnosis of primary central nervous system lymphoma from glioblastoma.

Authors:  Ji Ye Lee; Atle Bjørnerud; Ji Eun Park; Bo Eun Lee; Joo Hyun Kim; Ho Sung Kim
Journal:  Eur Radiol       Date:  2019-03-15       Impact factor: 5.315

Review 8.  Accuracy of percentage of signal intensity recovery and relative cerebral blood volume derived from dynamic susceptibility-weighted, contrast-enhanced MRI in the preoperative diagnosis of cerebral tumours.

Authors:  Ananya Chakravorty; Timothy Steel; Joga Chaganti
Journal:  Neuroradiol J       Date:  2015-10-16

9.  Utility of Percentage Signal Recovery and Baseline Signal in DSC-MRI Optimized for Relative CBV Measurement for Differentiating Glioblastoma, Lymphoma, Metastasis, and Meningioma.

Authors:  M D Lee; G L Baird; L C Bell; C C Quarles; J L Boxerman
Journal:  AJNR Am J Neuroradiol       Date:  2019-08-01       Impact factor: 3.825

10.  Metastatic breast carcinoma mimicking basal skull meningioma.

Authors:  Gregory W Schmidt; Neil R Miller
Journal:  Clin Ophthalmol       Date:  2007-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.